Abstract 1732
Background
We investigated the safety and efficacy of bendamustine-rituximab (BR) in previously untreated symptomatic and advanced CLL patients, as there is no data available on BR from Indian subcontinent.
Methods
This retrospective study included 120 consecutive treatment naïve patients with CLL without del (17p), who were registered at Department of Medical Oncology, AIIMS between January 2010 and to July 2018. Bendamustine was given at a dose of 90 mg/m2on day 1 and 2, combined with rituximab 375 mg/m2 rituximab on day 1, every 28 days for up to 6 courses. Event free survival (EFS) was defined as date of treatment to date of relapse, disease progression or death due to any cause.
Results
The median age was 57 years (range: 30-75 years). As per clinical Rai stage 30(25%) patients were in stage II, 42(35%) were in stage III and 48(40%)were in stage IV. ZAP-70 was positive (>20%) in 50%, CD 38 was positive (>30%) in 33%, and CD49d was positive (>30%) in 49% of cases. Beta-2 microglobulin (B2M) was elevated (≥3.5 mg/L) in 80% of cases. Fifty five cases (50%, n = 110) were IGHV mutated. The mean number of cycles was 5 (1-6). Overall response rate (ORR) seen with BR was 90% and complete response was 45%. Median event free survival was 24 months with a median follow up period of 29 months. Haemoglobin (<10g/dL), elevated B2 M, unmutated IGHV had statistically significant adverse impact on EFS on univariate analysis but on multivariate analysis only IGHV mutation status was found to had significance on EFS. The median EFS was 27 months in IGVH mutaed vs 18 months in IGHV unmutated-CLL patients (p = 0.001). Grade III/IV neutropenia, thrombocytopenia, anaemia and infections were observed in 12%, 8%, 7.5% and 10% respectively. The most common non -haematological toxicity was skin rash which was observed grade I/II in 24 cases ( 20%) and grade III/IV in 12 cases (10%).
Conclusions
This is the first study of Asia to demonstrate safety and efficacy of BR in symptomatic CLL patients. BR is effective and safe regimen in the first-line treatment of CLL. Unmutaed- CLL patients have inferior EFS than mutated - CLL patients. Skin toxicity was the most common adverse effect seen in our population which was observed in around one third of cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract
2459 - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study
Presenter: Vauleon Enora
Session: Poster Display session 1
Resources:
Abstract
4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.
Presenter: Gouri Shankar Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
1352 - Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Presenter: Michael Mark
Session: Poster Display session 1
Resources:
Abstract
6002 - Infection-Related Mortality in Different Types of Cancers
Presenter: Mohamed Gouda
Session: Poster Display session 1
Resources:
Abstract
5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy
Presenter: Edith Borcoman
Session: Poster Display session 1
Resources:
Abstract
3097 - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)
Presenter: Angeli Angeli
Session: Poster Display session 1
Resources:
Abstract
856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity
Presenter: Ayumu Matsuoka
Session: Poster Display session 1
Resources:
Abstract
1662 - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
Presenter: Trudi Schaper
Session: Poster Display session 1
Resources:
Abstract
2766 - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Presenter: Teppei Yamada
Session: Poster Display session 1
Resources:
Abstract